natgillin/translations-raw huggingface dataset:
However, Aerivio Spiromax should not be used to relieve an attack of breathlessness or wheezing. 
Međutim, Aerivio Spiromax se ne smije koristiti za ublažavanje samog napadaja nedostatka zraka ili piskanja pri disanju.
Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 22%; p<0.001) and 18% (95% CI: 11% to 24%; p<0.001) respectively. 
Salmeterol i FP značajno su smanjili stope egzacerbacija u usporedbi s placebom za 15% (95% CI: 7% do 22%; p<0,001) odnosno 18% (95% CI: 11% do 24%;
The respective mechanisms of action of both active substances are discussed below. 
Mehanizmi djelovanja te dvije djelatne tvari opisani su niže.
Do not breathe out through your inhaler. 
Nemojte izdisati kroz inhalator.
The data presented below refer to a lower dose of the fixed-dose combination containing these two actives, a dose and strength which is not available for Aerivio Spiromax. 
Niže prikazani podaci odnose se na nižu dozu fiksne kombinacije koja sadrži ove dvije djelatne tvari, dok Aerivio Spiromax nije dostupan u toj dozi i jačini.
• Cataract (cloudy lens in the eye). 
• katarakta (zamućenje očne leće)
Aerivio Spiromax is not likely to affect your ability to drive or use machines. 
Nije vjerojatno da će Aerivio Spiromax utjecati na Vašu sposobnost upravljanja vozilima ili rada sa
The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic 
Kombinaciju treba izbjegavati, osim kada korist nadmašuje povećani rizik od sistemskih nuspojava kortikosteroida, a u tom slučaju bolesnike je potrebno pratiti radi eventualnih sistemskih učinaka kortikosteroida.
If you stop using Aerivio Spiromax 
Ako prestanete primjenjivati Aerivio Spiromax
Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4fold Cmax and 15-fold AUC). 
Istodobna primjena ketokonazola (400 mg peroralno jedanput dnevno) i salmeterola (inhalacija 50 mikrograma dvaput dnevno) u 15 zdravih ispitanika tijekom 7 dana dovela je do značajnog povećanja izloženosti salmeterolu u plazmi (za 1,4 puta Cmax i za 15 puta AUC).
Aerivio Spiromax is not recommended for use in either children aged 12 years of age and younger or in adolescents aged 13 to 17 years. 
Aerivio Spiromax se ne preporučuje za primjenu ni u djece u dobi od 12 godina i mlađe niti u adolescenata u dobi od 13 do 17 godina.
This may help to stop you getting thrush in your mouth and/or becoming hoarse. 
To može pomoći u sprječavanju nastanka soora u ustima (gljivična infekcija kandidom) i/ili promuklosti.
Combined asthma-related death or life-threatening experience 
Kombinirano smrt ili životno ugrožavajući događaj povezani s astmom Bolesnici koji uzimaju inhalacijske
If a patient with severe COPD has experienced pneumonia, treatment with Aerivio Spiromax should be re-evaluated. 
Ako bolesnik s teškim KOPB-om dobije pneumoniju, potrebno je ponovno procijeniti liječenje Aerivio Spiromaxom.
If you feel more wheezy, your chest feels tight more often or you need to use more of your fast-acting ‘reliever' medicine, your chest condition may be getting worse and you could become seriously ill. You should continue to take Aerivio Spiromax but do not increase the number of puffs you take. 
Ako osjećate da je piskanje pri disanju jače, ako češće imate osjećaj stezanja u prsištu ili više koristite brzodjelujući lijek za ublažavanje simptoma, stanje Vaših pluća možda se pogoršava i mogli biste se ozbiljno razboljeti.
In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been 
U bolesnika s astmom ili KOPB-om opažen je niži stupanj sistemske izloženosti udahnutom flutikazonpropionatu.
GOAL showed more patients treated with salmeterol/fluticasone propionate achieved asthma control than patients treated with inhaled corticosteroid (ICS) alone and this control was attained at a lower corticosteroid dose. 
Ispitivanje GOAL pokazalo je da je kontrolu astme postiglo više bolesnika liječenih salmeterolom/flutikazonpropionatom nego bolesnika liječenih samo inhalacijskim kortikosteroidom i ta je kontrola bila uspostavljena pri nižoj dozi kortikosteroida.
Therapy should be down-titrated under physician supervision. 
Terapiju treba postupno snižavati na manju dozu pod liječničkim nadzorom.
Co-administration of erythromycin (500 mg orally three times a day) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 6 days resulted in a small but non-statistically significant increase in salmeterol exposure (1.4-fold Cmax and 1.2-fold AUC). 
Istodobna primjena eritromicina (500 mg peroralno tri puta na dan) i salmeterola (inhalacija 50 mikrograma dvaput dnevno) u 15 zdravih ispitanika tijekom 6 dana dovela je do malog, ali ne i statistički značajnog povećanja izloženosti salmeterolu (za 1,4 puta Cmax i za 1,2 puta AUC).
Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, acute adrenal crisis and growth retardation in children and adolescents and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression. 
Mogući sistemski učinci uključuju Cushingov sindrom, kušingoidni izgled, supresiju nadbubrežne žlijezde, akutnu adrenalnu krizu i usporen rast u djece i adolescenata, a rjeđe niz psihičkih učinaka i učinaka na ponašanje uključujući psihomotornu hiperaktivnost, poremećaje spavanja, anksioznost, depresiju i agresivnost.
For patients with COPD experiencing exacerbations, treatment with systemic corticosteroids is typically indicated, therefore patients should be instructed to seek medical attention if symptoms deteriorate with 
Bolesnicima s KOPB-om koji imaju egzacerbacije obično je indicirano liječenje sistemskim kortikosteroidima; stoga bolesnicima treba savjetovati da potraže liječničku pomoć ako im se simptomi pogoršavaju uz Aerivio Spiromax.
The inhaler is white with a semi-transparent yellow mouthpiece cover. 
Inhalator je bijeli, s poluprozirnim žutim poklopcem nastavka za usta.
Do not open and close the mouthpiece cover unless you are about to use your inhaler. 
Nemojte otvarati i zatvarati nastavak za usta osim ako se ne spremate
The increased incidence of reported pneumonia with salmeterol/fluticasone propionate 50/250 micrograms twice daily appears to be of similar magnitude to the incidence reported following treatment with salmeterol/fluticasone propionate 50/500 micrograms twice daily in TORCH. 
Povećana incidencija zabilježenih pneumonija sa salmeterolom/flutikazonpropionatom u dozi od 50/250 mikrograma dvaput dnevno čini se veličinom slične zabilježenoj incidenciji nakon liječenja salmeterolom/flutikazonpropionatom u dozi od 50/500 mikrograma dvaput dnevno u ispitivanju TORCH.
When to start using a new Aerivio Spiromax 
Kada početi koristiti novi Aerivio Spiromax
Adverse event profiles were similar with the exception of a higher incidence of pneumonias and known local side effects (candidiasis and dysphonia) in the salmeterol/fluticasone propionate 50/250 micrograms twice daily group compared with salmeterol. 
Profili nuspojava bili su slični uz iznimku više incidencije pneumonija i poznatih lokalnih nuspojava (kandidijaze i disfonije) u skupini liječenoj salmeterolom/flutikazonpropionatom u dozi od 50/250 mikrograma dvaput dnevno u usporedbi sa salmeterolom.
In a 12-week trial of children aged 4 to 11 years [n=257] treated with either salmeterol/fluticasone propionate 50/100 or salmeterol 50 micrograms + fluticasone propionate 100 micrograms both twice daily, both treatment arms experienced a 14% increase in peak expiratory flow rate as well as improvements in symptom score and rescue salbutamol use. 
U 12-tjednom ispitivanju u djece u dobi od 4 do 11 godina [n=257] liječene salmeterolom/flutikazonpropionatom 50/100 ili salmeterolom 50 mikrograma + flutikazonpropionatom 100 mikrograma dvaput dnevno, u obje je terapijske skupine nastupilo povećanje vršnog ekspiratornog protoka za 14%, kao i poboljšanje skora simptoma te primjene salbutamola za brzo ublažavanje simptoma.
• Low blood pressure and seizures (fits) 
• nizak krvni tlak i napadaje.
The following side effects have also been reported in patients with chronic obstructive pulmonary disease (COPD): 
Sljedeće nuspojave također su zabilježene u bolesnika s kroničnom opstruktivnom plućnom bolešću
Close your lips around the mouthpiece. 
Obuhvatite usnama nastavak za usta.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of the inhaled corticosteroid and therefore a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is required. 
Kad simptomi astme budu pod kontrolom, može se razmotriti postupno snižavanje doze inhalacijskog kortikosteroida i stoga je potrebna zamjena drugom fiksnom kombinacijom salmeterola i flutikazonpropionata koja sadrži nižu dozu inhalacijskog kortikosteroida.
One inhalation of 50 micrograms salmeterol and 500 micrograms fluticasone propionate twice daily. 
Jedna inhalacija od 50 mikrograma salmeterola i 500 mikrograma flutikazonpropionata primijenjena dvaput dnevno.
• Write the date you opened the foil pouch on the label on the inhaler. 
• Na naljepnicu na inhalatoru zapišite datum kada ste otvorili folijsku vrećicu.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk 
Nema kliničkog dokaza ne temelju kojeg se može se donijeti konačan zakjučak da se inhalacijski kortikosteroidni lijekovi unutar iste međusobno razlikuju po veličini rizika od pneumonije.
Medium dose ICS (>500 to 1000 micrograms 
Srednja doza inhalacijskog kortikosteroida (>500 do 1000 mikrograma BDP-a ili
Once control of asthma is attained treatment should be reviewed and consideration given as to whether patients should be stepped down to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid and then ultimately to an inhaled corticosteroid alone. 
Kad se postigne kontrola astme, potrebno je revidirati terapiju i razmotriti je li ju u bolesnika potrebno smanjivati na način da se zamijeni fiksnom kombinacijom salmeterola i flutikazonpropionata koja sadrži nižu dozu inhalacijskog kortikosteroida i naposljetku samo inhalacijskim kortikosteroidom.
There was no significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3% salmeterol/fluticasone propionate; hazard ratio for salmeterol/fluticasone propionate vs placebo: 1.22, 95% 
Nije bilo značajne razlike u vjerojatnosti koštanog prijeloma (5,1% placebo, 5,1% salmeterol, 5,4% FP i 6,3% salmeterol/flutikazonpropionat; omjer hazarda za salmeterol/flutikazonpropionat naspram placeba: 1,22, 95% CI: 0,87 do 1,72, p=0,248).
Symptomatic mouth and throat candidiasis can be treated with topical antifungal therapy whilst still continuing with Aerivio Spiromax. 
Simptomatska kandidijaza usta i grla može se liječiti topikalnim antimikoticima dok se istodobno može nastaviti terapija Aerivio Spiromaxom.
However, do not change the number of inhalations your doctor has prescribed without talking to your doctor first. 
Vam je liječnik propisao a da o tome prvo niste razgovarali s liječnikom.
Aerivio Spiromax is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age. 
Aerivio Spiromax nije indiciran za primjenu u djece u dobi od 12 godina i mlađih ili adolescenata u dobi od 13 do 17 godina.
Salmeterol/fluticasone propionate COPD - clinical trials TORCH was a 3-year study to assess the effect of treatment with salmeterol/fluticasone propionate inhalation powder 50/500 micrograms twice daily, salmeterol inhalation powder 50 micrograms twice daily, fluticasone propionate (FP) inhalation powder 500 micrograms twice daily or placebo on all-cause mortality in patients with COPD. 
Klinička ispitivanja salmeterola/flutikazonpropionata u KOPB-u TORCH je bilo ispitivanje u trajanju od 3 godine u kojem se procijenio učinak liječenja praškom inhalata salmeterola/flutikazonpropionata u dozi od 50/500 mikrograma dvaput dnevno, praškom inhalata salmeterola u dozi od 50 mikrograma dvaput dnevno, praškom inhalata flutikazonpropionata (FP) u dozi od 500 mikrograma dvaput dnevno ili placeba na smrtnost svih uzroka u bolesnika s KOPB-om.
In the subset of steroid naive asthmatics the time to an individual well controlled week was 16 days in the salmeterol/fluticasone propionate treatment compared with 23 days following treatment with ICS. 
U podskupini ispitanika s astmom koji nikad prije nisu bili liječeni inhalacijskim kortikosteroidom, vrijeme do individualnog dobro kontroliranog tjedna iznosilo je 16 dana u skupini koja je primala liječenje salmeterolom/flutikazonpropionatom u usporedbi s 23 dana kod liječenja inhalacijskim kortikosteroidom.
Regular review of patients as treatment is stepped down is important. 
Važno je redovito pregledavati bolesnike kod smanjivanja doze.
Aerivio Spiromax contains salmeterol and fluticasone propionate, which have differing modes of action. 
Mehanizam djelovanja i farmakodinamički učinci Aerivio Spiromax sadrži salmeterol i flutikazonpropionat, koji imaju drugačije načine djelovanja.
Symptomatic candidiasis of the mouth and throat can be treated with topical anti-fungal therapy whilst still continuing with Aerivio Spiromax. 
Simptomatska kandidijaza usta i grla može se liječiti topikalnim antimikoticima dok se istodobno može nastaviti terapija Aerivio
Appropriate treatment should be promptly 
Ako je indicirano, potrebno je odmah uvesti
Use your fast acting ‘reliever' inhaler to help your breathing and tell your doctor straight away. 
Uzmite inhalator s brzodjelujućim lijekom za ublažavanje simptoma kako bi Vam pomogao s disanjem i odmah
System Organ Class Adverse reaction 
Klasifikacija organskih sustava
The recommended dose is: 
Druge su nuspojave navedene niže:
White inhaler with a semi-transparent yellow mouthpiece cover. 
Bijeli inhalator s poluprozirnim žutim poklopcem nastavka za usta.
TC 
C.
Tell your doctor if you are taking the following medicines, before starting to use Aerivio Spiromax: 
Obavijestite svog liječnika, prije nego što počnete primjenjivati Aerivio Spiromax, ako uzimate sljedeće
Your doctor, nurse or pharmacist should provide you with training on how to use your inhaler, including how to take a dose effectively. 
Vas podučiti kako koristiti inhalator, uključujući i kako učinkovito uzimati dozu.
Therefore, concomitant use should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. 
Stoga je potrebno izbjegavati njihovu istodobnu primjenu, osim ako je moguća korist za bolesnika veća od rizika sistemskih nuspojava kortikosteroida.
Both hoarseness and the incidence of candidiasis of the mouth and throat may be relieved by rinsing the mouth with water and spitting the water out and/or brushing the teeth after using the product. 
I promuklost i incidencija kandidijaze usta i grla mogu se smanjiti tako da se nakon primjene lijeka usta isperu vodom i ta voda ispljune i/ili da se operu zubi.
Aerivio Spiromax should only be used to treat severe asthma in adults aged 18 years and older and 
Aerivio Spiromax smije se primjenjivati samo za liječenje teške astme u odraslih u dobi od 18 godina i starijih te odraslih s KOPB-om.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku, ljekarniku ili medicinskoj
[3%] vs 1 [<1%]) and a similar incidence of inhaled corticosteroid related adverse events (e.g. oral candidiasis - 6 [6%] vs 16 [8%], hoarseness - 2 [2%] vs 4 [2%]) compared with one inhalation twice daily. 
Ispitivanje je pokazalo da je udvostručavanje broja inhalacija za svaku pojedinu jačinu salmeterola/flutikazonpropionata tijekom najviše 14 dana rezultiralo malim povećanjem nuspojava povezanih s β-agonistom (tremor - 1 bolesnik [1%] naspram 0, palpitacije - 6 [3%] naspram 1 [<1%], mišićni grčevi - 6 [3%] naspram 1 [<1%]) i sličnom incidencijom nuspojava povezanih s inhalacijskim kortikosteroidom (npr. oralna kandidijaza- 6 [6%] naspram 16 [8%], promuklost- 2 [2%] naspram 4 [2%]) u usporedbi s jednom inhalacijom dvaput dnevno.
Reported over 3 years in a COPD study 
Vrlo često zabilježene uz placebo Zabilježene tijekom 3 godine u ispitivanju KOPB-a
Pneumonia (in COPD patients) 
Pneumonija u bolesnika s KOPB-om
- patients not adequately controlled on a lower strength corticosteroid combination product 
- bolesnici u kojih bolest nije odgovarajuće kontrolirana primjenom kombiniranog lijeka koji sadrži
The combination should be avoided unless the benefit outweighs the increased risk of systemic glucocorticoid undesirable effects. 
Tu kombinaciju treba izbjegavati osim ako je korist veća od povećanog rizika od sistemskih nuspojava glukokortikoida.
- if you are allergic (hypersensitive) to salmeterol, fluticasone propionate or any of the other ingredients of this medicine (listed in section 6). 
Što morate znati prije nego počnete primjenjivati Aerivio Spiromax Nemojte primjenjivati Aerivio Spiromax: - ako ste alergični (preosjetljivi) na salmeterol, flutikazonpropionata ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
What you need to know before you use Aerivio Spiromax 
Što je Aerivio Spiromax i za što se koristi Što morate znati prije nego počnete primjenjivati Aerivio Spiromax Kako primjenjivati Aerivio Spiromax
Aerivio Spiromax is indicated in adults 18 years of age and older only. 
Aerivio Spiromax je indiciran samo u odraslih u dobi od 18 godina i starijih.
Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder salmeterol/fluticasone propionate 
Aerivio Spiromax 50 mikrograma/500 mikrograma prašak inhalata salmeterol/flutikazonpropionat
An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. 
U bolesnika s KOPB-om koji primaju inhalacijske kortikosteroide opažena je povećana incidencija pneumonije, uključujući i hospitalizaciju zbog pneumonije.
Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat and, rarely, of the oesophagus, can occur in some patients. 
Zbog komponente flutikazonpropionata, u nekih bolesnika mogu nastati promuklost i kandidijaza (soor) usta i grla, a rijetko i jednjaka.
Hold your inhaler with the semi-transparent yellow mouthpiece cover at the bottom. 
Držite inhalator tako da poluprozirni poklopac nastavka za usta bude dolje.
Your doctor may prescribe an anti-fungal medicine to treat the thrush. 
Liječnik Vam može propisati antimikotik za
Aerivio Spiromax is for the treatment of patients with severe asthma only. 
Aerivio Spiromax namijenjen je samo za liječenje bolesnika s teškom astmom.
When it is appropriate to titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is 
Kada je dozu primjereno titrirati na manju od one dostupne u ovom lijeku, Aerivio Spiromax je potrebno zamijeniti drugom fiksnom kombinacijom salmeterola i flutikazonpropionata koja sadrži nižu dozu inhalacijskog kortikosteroida.
Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat and, rarely of the oesophagus, can occur in some patients. 
Zbog komponente flutikazonpropionata, u nekih bolesnika mogu nastati promuklost i kandidijaza (soor) usta i grla, te rijetko jednjaka.
Keep the mouthpiece cover closed after removal of the foil wrap. 
Poklopac nastavka za usta držati zatvorenim nakon uklanjanja omota od folije.
All patients should be provided with training by the prescribing Health Care Professional on how to use Aerivio Spiromax. 
Liječnik koji bolesnicima propisuje Aerivio Spiromax treba im omogućiti poduku o tome kako da ga koriste.
Rounded (moon shaped) face (Cushing's syndrome) Your doctor will check you regularly for any of these side effects and make sure you are taking the lowest dose of this combination of drugs to control your asthma. 
Liječnik će Vas redovito pregledavati zbog moguće pojave ovih nuspojava i paziti da uzimate najnižu dozu ove kombinacije lijekova za kontrolu
EXP Use within 3 months of removing from foil wrapping. 
Rok valjanosti Upotrijebiti unutar 3 mjeseca od otvaranja omota od folije.
Each delivered dose (the dose that leaves the mouthpiece) contains 45 micrograms of salmeterol (as salmeterol xinafoate) and 465 micrograms of fluticasone propionate. 
Jedna isporučena doza (doza koja izađe iz nastavka za usta) sadrži 45 mikrograma salmeterola (u obliku salmeterolksinafoata) i 465 mikrograma flutikazonpropionata.
Each metered dose contains 50 micrograms of salmeterol (as salmeterol xinafoate) and 500 micrograms of 
Jedna odmjerena doza sadrži 50 mikrograma salmeterola (u obliku salmeterolksinafoata) i 500 mikrograma
The mouthpiece cover is fixed to your inhaler and must not be taken off. Do not use your inhaler if it is damaged or if the mouthpiece has come apart from your inhaler. 
Nemojte koristiti inhalator ako je oštećen ili ako se nastavak za usta odvojio od inhalatora.
Serious asthma-related adverse events and exacerbations may occur during treatment with Aerivio Spiromax. 
Tijekom liječenja Aerivio Spiromaxom mogu nastati ozbiljni štetni događaji povezani s astmom i egzacerbacije.
Studies SCO40043 and SCO100250 were randomised, double-blind, parallel-group, replicate studies comparing the effect of salmeterol/fluticasone propionate 50/250 micrograms twice daily (a dose not licensed for COPD treatment in the European Union) with salmeterol 50 micrograms twice daily, on the annual rate of moderate/severe exacerbations in subjects with COPD with FEV1 less than 50% predicted and a history of exacerbations. 
Ispitivanja SCO40043 i SCO100250 bila su randomizirana, dvostruko slijepa ispitivanja na usporednim skupinama koja su ponovno usporedila učinak salmeterola/flutikazonpropionata u dozi od 50/250 mikrograma dvaput dnevno (doza koja nije odobrena za liječenje KOPB-a u Europskoj
Aerivio Spiromax is indicated for use in adults aged 18 years and older only. 
Aerivio Spiromax je indiciran samo za primjenu u odraslih u dobi od 18 godina i starijih.
Each delivered dose (the dose from the mouthpiece) contains 45 micrograms of salmeterol (as salmeterol xinafoate) and 465 micrograms of fluticasone propionate. 
Jedna isporučena doza (doza iz nastavka za usta) sadrži 45 mikrograma salmeterola (u obliku salmeterolksinafoata) i 465 mikrograma flutikazonpropionata.
Parodoxical bronchospasm 
respiratorni simptomi (bronhospazam)
Aerivio Spiromax should be used correctly in order to achieve effective treatment. 
Da bi se ostvarilo učinkovito liječenje, Aerivio Spiromax treba ispravno koristiti.
It is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed-dose combination can be used in patients with severe asthma. 
Prije nego što se primijeni bilo koja fiksna kombinacija u bolesnika s teškom astmom, preporučuje se ustanoviti odgovarajuću dozu inhalacijskog kortikosteroida.
Some medicines may increase the effects of Aerivio Spiromax and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). 
Vaše stanje ukoliko uzimate te lijekove (uključujući lijekove za liječenje HIV infekcije: ritonavir, kobicistat).
• Bruising and fractures. 
• mučnina i proljev
FP 
KOPB
Aerivio Spiromax 50 micrograms/500 micrograms inhalation powder 
Aerivio Spiromax 50 mikrograma/500 mikrograma prašak inhalata
Tachycardia 
Salmeterol